This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

ICAD Reports Third Quarter Financial Results

Stocks in this article: ICAD

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and nine months ended September 30, 2013.

“iCAD delivered another quarter of strong operating performance. Third quarter revenue of $8.3 million was the highest since we began executing on our broadened oncology strategy more than two years ago. We also demonstrated improvements in both the Cancer Detection and Therapy businesses, and continued to achieve positive adjusted EBITDA,” said Ken Ferry, President and CEO of iCAD.

“Our Therapy business performed well as evidenced by significant increases in year-to-date revenue, product placements and utilization. Market adoption has been particularly strong for the treatment of non-melanoma skin cancer. Positive three-year data using the Xoft System to treat skin cancer that was reported at ASTRO showed effective long-term treatment with no recurrences and excellent cosmetic outcomes. We are confident that with ongoing positive clinical data combined with growing favorable reimbursement, we remain well positioned to continue strong growth in the Therapy business.

“For the third quarter, revenue at our Cancer Detection business grew 14% over the prior year, with double-digit growth in both product and service and supply revenue. We believe our service business growth of 18% clearly demonstrates success with our strategy to increase recurring revenue. Finally, we are seeing considerable traction from PowerLook, our next-generation mammography CAD platform, from both new customers and upgrades from our growing installed base.

“We are very pleased with our performance to date in 2013 across both of our businesses. We remain steadfast in our goal to drive revenue growth in the Therapy and Cancer Detection businesses through appropriate investments combined with disciplined financial management,” concluded Mr. Ferry.

Third Quarter Financial Results

Revenue: Total revenue for the third quarter of 2013 increased to $8.3 million from $8.2 million for the third quarter of 2012, due to an increase in Cancer Detection revenue partially offset by a decline in Therapy revenue.

Cancer Detection revenue included film, digital mammography, MRI and CT CAD platforms, as well as service and supply revenue from these products. Therapy revenue included Xoft ® Axxent ® Electronic Brachytherapy System ® product sales, as well as the associated service and supply revenue.

Three months ended September 30,
        2013     2012     % Change

Detection revenue

       
Product revenue $ 2,246 $ 2,023 11.0 %
Service revenue   2,064       1,757     17.5 %
Total Revenue $ 4,310     $ 3,780     14.0 %
 

Therapy revenue

Product revenue $ 2,519 $ 3,638 (30.8 )%
Service revenue   1,461       765     91.0 %
Total Revenue $ 3,980     $ 4,403     (9.6 )%

Gross Margin: Gross profit for the third quarter of 2013 increased to $5.9 million, or 71.5% of revenue, from $5.8 million, or 71.9% of revenue, for the third quarter of 2012, primarily due to product mix, partially offset by the impact of the Medical Device Excise Tax, which went into effect in 2013.

Operating Expenses: Total operating expenses for the quarter ended September 30, 2013 declined to $6.3 million from $6.6 million for the same period in 2012, as a result of ongoing cost-control measures, partially offset by commercial and R&D investments.

Non-GAAP Adjusted EBITDA: Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was $545,000 for the third quarter of 2013, compared with non-GAAP adjusted EBITDA of $240,000 for the same period in 2012.

Net Loss: The net loss for the third quarter of 2013 was $589,000, or $0.05 per share, compared with a net loss for the third quarter of 2012 of $1.5 million, or $0.14 per share.

Non-GAAP Adjusted Net Loss: The non-GAAP adjusted net loss, as defined below, for the third quarter of 2013 was $1.2 million, or $0.11 per share, compared with a non-GAAP adjusted net loss for the third quarter of 2012 of $1.6 million, or $0.15 per share.

Cash and Cash Flow: As of September 30, 2013, iCAD had cash and cash equivalents of $10.2 million, compared with $12.9 million as of June 30, 2013 and $13.9 million as of December 31, 2012. Net cash used by operations for the first nine months of 2013 was $3.2 million.

Nine Month Financial Results

Revenue: Total revenue for the first nine months of 2013 increased 17.0% to $24.0 million from $20.5 million for the first nine months of 2012, including a 41.4% increase in Therapy revenue and a 1.6% increase in Cancer Detection revenue.

Nine months ended September 30,

        2013     2012     % Change

Detection revenue

       
Product revenue $ 6,566 $ 7,327 (10.4 )%
Service revenue   6,189       5,225     18.4 %
Total Revenue $ 12,755     $ 12,552     1.6 %
 

Therapy revenue

Product revenue $ 7,763 $ 5,921 31.1 %
Service revenue   3,414       1,984     72.1 %
Total Revenue $ 11,177     $ 7,905     41.4 %

Gross Margin: Gross profit for the first nine months of 2013 was $16.8 million, or 70.2% of revenue, compared with gross profit for the first nine months of 2012 of $14.5 million, or 70.8% of revenue.

Operating Expenses: Total operating expenses for the nine months ended September 30, 2013 declined to $18.0 million from $19.1 million for the same period in 2012.

Non-GAAP Adjusted EBITDA: Non-GAAP adjusted EBITDA for the first nine months of 2013 was $1.6 million, compared with a non-GAAP adjusted EBITDA loss of $1.6 million for the first nine months of 2012.

Net Loss: The net loss for the first nine months of 2013 was $3.2 million, or $0.30 per share, compared with a net loss for the first nine months of 2012 of $6.7 million, or $0.62 per share.

Non-GAAP Adjusted Net Loss: The non-GAAP adjusted net loss for the first nine months of 2013 was $3.7 million, or $0.34 per share, compared with a non-GAAP adjusted net loss for the first nine months of 2012 of $7.1 million, or $0.66 per share.

Use of Non-GAAP Financial Measures

In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's website at www.icadmed.com.

Conference Call

iCAD management will host an investment community conference call on Tuesday, October 29, 2013 beginning at 10:00 a.m. Eastern time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-680-0865 (domestic) or 617-213-4853 (international) and entering passcode 48869679. The call also will be broadcast live on the Internet at www.streetevents.com, www.earnings.com and www.icadmed.com.

A replay of the conference call will be accessible two hours after its completion through November 4, 2013 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 44988318. The call will also be archived for 90 days at www.streetevents.com, www.earnings.com and www.icadmed.com.

About iCAD, Inc.

iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD’s Xoft System offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. For more information, call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

-Tables to Follow -

iCAD, INC. AND SUBSIDIARY
           
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands except for share data)
 

September 30,

December 31,

Assets

2013

2012

 
Current assets:
Cash and cash equivalents $ 10,209 $ 13,948

Trade accounts receivable, net of allowance for doubtful accounts of $73 in 2013 and $48 in 2012

8,419 4,980
Inventory, net 2,003 2,119
Prepaid expenses and other current assets 658   486  
Total current assets 21,289   21,533  
 

Property and equipment, net of accumulated depreciation and amortization of $4,106 in 2013 and $3,627 in 2012

1,825 1,483
Other assets 475 638

Intangible assets, net of accumulated amortization of $12,034 in 2013 and $10,744 in 2012

13,963 15,230
Goodwill 21,109   21,109  
Total assets $ 58,661   $ 59,993  
 

Liabilities and Stockholders' Equity

Current liabilities:
Accounts payable $ 2,018 $ 1,940
Accrued and other expenses 3,515 4,142
Interest payable 569 499
Capital lease - short-term portion 130 -
Warrant liability 1,054 1,538
Deferred revenue 7,498   6,520  
Total current liabilities 14,784   14,639  
 
Deferred revenue, long-term portion 1,633 1,502
Other long-term liabilities 1,313 1,341
Capital lease - long-term portion 279 -
Notes payable 15,299   14,846  
Total liabilities 33,308   32,328  
 
 
Stockholders' equity:

Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.

- -

Common stock, $ .01 par value: authorized 85,000,000 shares; issued 11,036,075 in 2013 and 10,993,933 in 2012; outstanding 10,850,244 in 2013 and 10,808,102 in 2012

110 110
Additional paid-in capital 166,302 165,416
Accumulated deficit (139,644 ) (136,446 )
Treasury stock at cost, 185,831 shares in 2013 and 2012 (1,415 ) (1,415 )
Total stockholders' equity 25,353   27,665  
 
Total liabilities and stockholders' equity $ 58,661   $ 59,993  
iCAD, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands except for per share data)
               

Three Months Ended September 30,

Nine Months Ended September 30,
2013 2012 2013 2012
Revenue:
Products $ 4,765 $ 5,661

$

14,329 $ 13,248
Service and supplies 3,525   2,522   9,603   7,209  
Total revenue 8,290 8,183 23,932 20,457
 
Cost of revenue:
Products 1,383 1,527 4,184 3,603
Service and supplies 747 541 2,251 1,678
Amortization of acquired intangibles 234   233   701   698  

Total cost of revenue

2,364 2,301 7,136 5,979
       
Gross profit 5,926   5,882   16,796   14,478  
 
Operating expenses:
Engineering and product development 2,112 1,971 5,734 6,158
Marketing and sales 2,617 2,842 7,392 7,976
General and administrative 1,551   1,773   4,825   4,971  
Total operating expenses 6,280 6,586 17,951 19,105
       
Loss from operations (354 ) (704 ) (1,155 ) (4,627 )
 
Gain from change in fair value of warrant 624 126 484 512
Interest expense (807 ) (883 ) (2,467 ) (2,549 )
Other income 4   9   16   27  
Other expense, net (179 ) (748 ) (1,967 ) (2,010 )
 
Loss before income tax expense (533 ) (1,452 ) (3,122 ) (6,637 )
 
Income tax expense (56 ) (13 ) (76 ) (35 )
       
Net loss and comprehensive loss $ (589 ) $ (1,465 ) $ (3,198 ) $ (6,672 )
 
Net loss per share:
Basic and diluted $ (0.05 ) $ (0.14 ) $ (0.30 ) $ (0.62 )
 

Weighted average number of shares used in computing loss per share:

Basic and diluted 10,849   10,805   10,835   10,792  
 

iCAD, INC. AND SUBSIDIARY

     
Condensed Consolidated Statements of Cash Flows
(unaudited)
For the nine months ended September 30,

2013

2012
(in thousands)
Cash flow from operating activities:
Net loss $ (3,198 ) $ (6,672 )

Adjustments to reconcile net loss to net cash used for operating activities:

Depreciation 528 701
Amortization 1,291 1,472
Bad debt provision 35 -
Gain from change in fair value of warrant (484 ) (512 )
Loss on disposal of assets 49 143
Stock-based compensation expense 908 731
Amortization of debt discount and debt costs 588 761
Interest on settlement obligations 214 313
Changes in operating assets and liabilities:
Accounts receivable (3,474 ) (1,712 )
Inventory 116 178
Prepaid and other current assets (145 ) 215
Accounts payable 78 1,106
Accrued expenses (799 ) (2,172 )
Deferred revenue 1,110   818  
Total adjustments 15   2,042  
 
Net cash used for operating activities (3,183 ) (4,630 )
 
Cash flow from investing activities:
Additions to patents, technology and other (24 ) (3 )
Additions to property and equipment (510 ) (465 )
Net cash used for investing activities (534 ) (468 )
 
Cash flow from financing activities:
Issuance of common stock for cash 3 -
Taxes paid related to restricted stock issuance (25 ) (13 )
Proceeds from debt financing, net -   14,325  
Net cash (used for) provided by financing activities (22 ) 14,312  
 
Increase (decrease) in cash and equivalents (3,739 ) 9,214
Cash and equivalents, beginning of period 13,948   4,576  
Cash and equivalents, end of period $ 10,209   $ 13,790  

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO COMPARABLE GAAP MEASURES

(Unaudited, in thousands, except per share amounts)

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs